Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2018 08:00 ET | Source: Versartis, Inc.

Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics

- Tolerability and proof-of-mechanism for lead candidate AVB-S6-500, a novel GAS6-AXL pathway inhibitor, established in ongoing Phase 1 clinical study - Multi-study clinical development program in...
May 08, 2018 16:15 ET | Source: Versartis, Inc.

Versartis Reports First Quarter 2018 Financial Results

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended...
March 01, 2018 16:05 ET | Source: Versartis, Inc.

Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

MENLO PARK, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the fourth quarter and...
October 26, 2017 16:05 ET | Source: Versartis, Inc.

Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has retained Cowen to assist in...
October 26, 2017 16:05 ET | Source: Versartis, Inc.

Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the third quarter ended...
September 21, 2017 16:30 ET | Source: Versartis

Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint

MENLO PARK, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
September 07, 2017 16:05 ET | Source: Versartis

Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017

MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
September 05, 2017 16:05 ET | Source: Versartis

Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs

MENLO PARK, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
August 02, 2017 08:30 ET | Source: Versartis

Versartis to Present at the Canaccord Genuity Growth Conference

MENLO PARK, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
July 27, 2017 16:05 ET | Source: Versartis

Versartis Reports Second Quarter 2017 Financial Results

MENLO PARK, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...